Genenta Science S.p.A. (NASDAQ:GNTA – Get Free Report) shares rose 1.3% during trading on Monday . The company traded as high as $4.09 and last traded at $3.88. Approximately 7,344 shares traded hands during mid-day trading, a decline of 31% from the average daily volume of 10,682 shares. The stock had previously closed at $3.83.
Genenta Science Stock Up 1.3 %
The company’s fifty day simple moving average is $4.59 and its two-hundred day simple moving average is $4.60.
Genenta Science Company Profile
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.
See Also
- Five stocks we like better than Genenta Science
- Investing In Preferred Stock vs. Common Stock
- Merck: 4 No-Brainer Reasons to Buy This Dip
- How to buy stock: A step-by-step guide for beginners
- Ackman Announces Major Stake in Uber: Should You Follow His Lead?
- What is the Nasdaq? Complete Overview with History
- Wells Fargo Upgraded These 3 Stocks—Here’s Why They Stand Out
Receive News & Ratings for Genenta Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genenta Science and related companies with MarketBeat.com's FREE daily email newsletter.
